Journal
ACTA HAEMATOLOGICA
Volume -, Issue -, Pages -Publisher
KARGER
DOI: 10.1159/000510281
Keywords
Myeloproliferative neoplasm; t(8; 9)(p22; p24); JAK2 kinase inhibitor; Ruxolitinib
Categories
Ask authors/readers for more resources
The translocation t(8;9) generates the fusion gene PCM1-JAK2, leading to continuous activation of JAK2 tyrosine kinase. t(8;9)/PCM1-JAK2 is the most common myelodysplastic/myeloproliferative neoplasm. Patients with this abnormality have similar features and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment. However, the long-term remission results of ruxolitinib are varied, so it is important to determine the response to ruxolitinib. This study describes a patient with eosinophilia-associated myeloproliferative neoplasm with t(8;9)(p21;p24), who has achieved sustained response for >1 year since the administration of ruxolitinib.
The translocation t(8;9) produces the fusion gene PCM1-JAK2, resulting in the continuous activation of the JAK2 tyrosine kinase. Myelodysplastic/myeloproliferative neoplasms are the most common disease with t(8;9)/PCM1-JAK2. Individuals with this abnormality have similar features, and JAK2 kinase inhibitor (ruxolitinib) is an effective treatment of the condition. The long-term remission results of ruxolitinib are varied. It is important to determine the response to ruxolitinib. Here, we describe a patient who has been diagnosed with eosinophilia-associated myeloproliferative neoplasm with t(8;9)(p21;p24). This patient has achieved sustained response for >1 year since the administration of ruxolitinib.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available